宫癌患者放射治疗使用趋势和实施挑战:日本大阪的一项多中心研究
Toshiki Ikawa1,2, Toshitaka Morishima1, Kayo Nakata1
1Cancer Control Center, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka 541-8567, Japan.
Journal of radiation research
|November 10, 2025
概括
在日本大阪,对于宫癌的放射治疗使用正在增加,特别是对于晚期的癌症. 然而,放射治疗治疗的增加在各机构之间存在差异,这凸显了对支臂疗法服务的进一步研究的需要.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 妇科瘤学 妇科瘤学
背景情况:
- 日本于2018年修订了宫癌的分期和指导方针.
- 分析了大阪府宫癌放射治疗的趋势.
研究的目的:
- 分析大阪府宫癌放射治疗使用趋势.
- 为了确定治疗方式和阶段分布的变化.
主要方法:
- 使用了医院癌症登记数据 (2016-2023年) 与诊断程序组合数据 (2019-2023年) 相关联.
- 包括患上上皮层或神经内分泌宫癌的患者,不包括0.0期.
- 分析了67家癌症护理医院的治疗趋势,阶段分布和放射治疗使用情况.
主要成果:
- 患者数量保持稳定,但晚期 (IIB,IIIC) 增加,而早期 (IB-IIA) 减少.
- 作为初始治疗的放射治疗从229 (2016) 增加到294 (2023),手术的同时下降.
- 放射治疗的比例在不同阶段显著增加:IB-IIA (11.9%至17.2%),IIB (55.6%至71.7%) 和IIIC (38.0%至69.5%).
结论:
- 在大阪观察到,宫癌的放射治疗使用趋势越来越大.
- 放射治疗的增加因机构而异,一些机构的病例数量稳定或下降.
- 需要进一步研究手臂治疗人员,设备可行性和集中来维持服务.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...


